Oncogenic mechanisms in Burkitt lymphoma

Cold Spring Harbor Perspectives in Medicine

Volumn 4, Issue 2, 2014, Pages

  Schmitz, Roland ^a   Ceribelli, Michele ^a   Pittaluga, Stefania ^a   Wright, George ^a   Staudt, Louis M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAKPOINT CLUSTER REGION PROTEIN; CYCLIN D3; CYCLIN DEPENDENT KINASE 6; INHIBITOR OF DIFFERENTIATION 3; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P53; PROTEIN TYROSINE PHOSPHATASE SHP 1; T CELL FACTOR PROTEIN;

ARTICLE; B LYMPHOCYTE; BURKITT LYMPHOMA; CANCER SPECIFIC SURVIVAL; CELL CYCLE PROGRESSION; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL FEATURE; GENE EXPRESSION; GENE MUTATION; GENE TRANSLOCATION; GENETICS; GENOMICS; GERMINAL CENTER; HUMAN; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; MOLECULAR GENETICS; PATHOGENESIS; SIGNAL TRANSDUCTION; SOMATIC MUTATION;

BURKITT LYMPHOMA; CYCLIN D3; GENES, MYC; GERMINAL CENTER; HUMANS; MUTATION; ONCOGENES; PHOSPHATIDYLINOSITOL 3-KINASES; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR 3;

EID: 84891764795     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a014282     Document Type: Article

References (61)

1. Adams JM, Harris AW, Pinkert CA, Corcoran LM, Alexander WS, Cory S, Palmiter RD, Brinster RL. 1985. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 318: 533-538.
2. Basso K, Dalla-Favera R. 2012. Roles of BCL6 in normal and transformed germinal center B cells. Immunol Rev 247: 172-183.
3. Beck K, Peak MM, Ota T, Nemazee D, Murre C. 2009. Distinct roles for E12 and E47 in B cell specification and the sequential rearrangement of immunoglobulin light chain loci. J Exp Med 206: 2271-2284.
4. Burkitt D. 1958. A sarcoma involving the jaws in African children. Br J Surg 46: 218-223.
5. Burkitt DP. 1961. Observations on the geography of malignant lymphoma. East Afr Med J 38: 511-514.
6. Burkitt D. 1962. A children's cancer dependent on climatic factors. Nature 194: 232-234.
7. Calado DP, Sasaki Y, Godinho SA, Pellerin A, Kochert K, Sleckman BP, de Alboran IM, Janz M, Rodig S, Rajewsky K. 2012 The cell-cycle regulator c-Myc is essential for the formation and maintenance of germinal centers. Nat Immunol 13: 1092-1100.
8. Casanovas O, Jaumot M, Paules AB, Agell N, Bachs O. 2004. P38SAPK2 phosphorylates cyclin D3 at Thr-283 and targets it for proteasomal degradation. Oncogene 23: 7537-7544.
9. Chene A, Donati D, Guerreiro-Cacais AO, Levitsky V, Chen Q, Falk KI, Orem J, Kironde F, Wahlgren M, Bejarano MT. 2007. A molecular link between malaria and Epstein-Barr virus reactivation. PLoS Pathog 3: e80.
10. Dalla-Favera R, Bregni M, Erikson J, Patterson D, Gallo RC, Croce CM. 1982. Human c-myc oncogene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci 79: 7824-7827.
11. Dalldorf G, Linsell CA, Barnhart FE, Martyn R. 1964. An epidemiologic approach to the lymphomas of African children and Burkitt's Sarcoma of the jaws. Perspect Biol Med 7: 435-449.
12. Dang CV. 2012. MYCon the path to cancer. Cell 149: 22-35.
13. Dave SS, Fu K, Wright GW, Lam LT, Kluin P, Boerma EJ, Greiner TC, Weisenburger DD, Rosenwald A, Ott G, et al. 2006. Molecular diagnosis of Burkitt's lymphoma. NEngl J Med 354: 2431-2442.
14. Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, Kastritis E, Gilpatrick T, Paranal RM, Qi J, et al. 2011. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146: 904-917.
15. Diehl JA, Zindy F, Sherr CJ. 1997. Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway. Genes Dev 11: 957-972.
16. Dominguez-Sola D, Victora GD, Ying CY, Phan RT, Saito M, Nussenzweig MC, Dalla-Favera R. 2012. The proto-oncogene MYC is required for selection in the germinal center and cyclic reentry. Nat Immunol 13: 1083-1091.
17. Donati D, Espmark E, Kironde F, Mbidde EK, Kamya M, Lundkvist A, Wahlgren M, Bejarano MT, Falk KI. 2006. Clearance of circulating Epstein-Barr virus DNA in children with acute malaria after antimalaria treatment. J Infect Dis 193: 971-977.
18. Evan GI, Wyllie AH, Gilbert CS, Littlewood TD, Land H, Brooks M, Waters CM, Penn LZ, Hancock DC. 1992. Induction of apoptosis in fibroblasts by c-Myc protein. Cell 69: 119-128.
19. Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, Morse EM, Keates T, Hickman TT, Felletar I, et al. 2010. Selective inhibition of BET bromodomains. Nature 468: 1067-1073.
20. Hemann MT, Bric A, Teruya-Feldstein J, Herbst A, Nilsson JA, Cordon-Cardo C, Cleveland JL, Tansey WP, Lowe SW. 2005. Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature 436: 807-811.
21. Hummel M, Bentink S, Berger H, Klapper W, Wessendorf S, Barth TF, Bernd HW, Cogliatti SB, Dierlamm J, Feller AC, et al. 2006. A biologic definition of Burkitt's lymphoma fromtranscriptional and genomic profiling. NEngl J Med 354: 2419-2430.
22. Illingworth J, Butler NS, Roetynck S, Mwacharo J, Pierce SK, Bejon P, Crompton PD, Marsh K, Ndungu FM. 2013. Chronic exposure to Plasmodiumfalciparum is associated with phenotypic evidence of B and T cell exhaustion. J Immunol 190: 1038-1047.
23. Kang MS, Soni V, Bronson R, Kieff E. 2008. Epstein-Barr virus nuclear antigen 1 does not cause lymphoma in C57BL/6 J mice. J Virol 82: 4180-4183.
24. Kee BL. 2009. E and ID proteins branch out. Nat Rev Immunol 9: 175-184.
25. Klapproth K, Sander S, Marinkovic D, Baumann B, Wirth T. 2009. The IKK2/NF-kB pathway suppresses MYCinduced lymphomagenesis. Blood 114: 2448-2458.
26. Küppers R. 2005. Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer 5: 251-262.
27. Kwon K, Hutter C, Sun Q, Bilic I, Cobaleda C, Malin S, Busslinger M. 2008. Instructive role of the transcription factor E2A in early B lymphopoiesis and germinal center B cell development. Immunity 28: 751-762.
28. Levens D. 2013. Cellular MYCro economics: Balancing MYC functionwithMYC expression. Cold Spring Harb Perspect Med 3: a014233.
29. Lin CY, Loven J, Rahl PB, Paranal RM, Burge CB, Bradner JE, Lee TI, Young RA. 2012. Transcriptional amplification in tumor cells with elevated c-Myc. Cell 151: 56-67.
30. Love C, Sun Z, Jima D, Li G, Zhang J, Miles R, Richards KL, Dunphy CH, Choi WW, Srivastava G, et al. 2012. The genetic landscape of mutations in Burkitt lymphoma. Nat Genet 44: 1321-1325.
31. MacLennan IC. 1994. Germinal centers. Annu Rev Immunol 12: 117-139.
32. Mertz JA, Conery AR, Bryant BM, Sandy P, Balasubramanian S, Mele DA, Bergeron L, Sims RJ. 2011. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci 108: 16669-16674.
33. Meyer N, Kim SS, Penn LZ. 2006. The Oscar-worthy role of Myc in apoptosis. Semin Cancer Biol 16: 275-287.
34. Morrow RH, Kisuule A, Pike MC, Smith PG. 1976. Burkitt's lymphoma in the Mengo Districts of Uganda: Epidemiologic features and their relationship to malaria. J Natl Cancer Inst 56: 479-483.
35. Murre C, McCaw PS, Baltimore D. 1989. A new DNA binding and dimerization motif in immunoglobulin enhancer binding, daughterless, MyoD, and myc proteins. Cell 56: 777-783.
36. Nie Z, Hu G, Wei G, Cui K, Yamane A, Resch W, Wang R, Green DR, Tessarollo L, Casellas R, et al. 2012. c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells. Cell 151: 68-79.
37. Olive V, Bennett MJ, Walker JC, Ma C, Jiang I, Cordon-Cardo C, Li QJ, Lowe SW, Hannon GJ, He L. 2009. miR-19 is a key oncogenic component of mir-17-92. Genes Dev 23: 2839-2849.
38. Orem J, Mbidde EK, Weiderpass E. 2008. Current investigations and treatment of Burkitt's lymphoma in Africa. Trop Doct 38: 7-11.
39. Pasqualucci L, Guglielmino R, Houldsworth J, Mohr J, Aoufouchi S, Polakiewicz R, Chaganti RS, Dalla-Favera R. 2004. Expression of the AID protein in normal and neoplastic B cells. Blood 104: 3318-3325.
40. Peled JU, Yu JJ, Venkatesh J, Bi E, Ding BB, Krupski-Downs M, Shaknovich R, Sicinski P, Diamond B, Scharff MD, et al. 2010. Requirement for cyclin D3 in germinal center formation and function. Cell Res 20: 631-646.
41. Rahl PB, Young RA. 2014. MYC and transcription elongation. Cold Spring Harb Perspect Med doi: 10.1101/cshperspect.a020990.
42. Ramiro AR, Jankovic M, Eisenreich T, Difilippantonio S, Chen-Kiang S, Muramatsu M, Honjo T, Nussenzweig A, Nussenzweig MC. 2004. AID is required for c-myc/ IgH chromosome translocations in vivo. Cell 118: 431-438.
43. Refaeli Y, Young RM, Turner BC, Duda J, Field KA, Bishop JM. 2008. The B cell antigen receptor and overexpression of MYC can cooperate in the genesis of B cell lymphomas. PLoS Biol 6: e152.
44. Richter J, Schlesner M, Hoffmann S, Kreuz M, Leich E, Burkhardt B, Rosolowski M, Ammerpohl O, Wagener R, Bernhart SH, et al. 2012. Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing. Nat Genet 44: 1316-1320.
45. Rowe M, Kelly GL, Bell AI, Rickinson AB. 2009. Burkitt's lymphoma: The Rosetta Stone deciphering Epstein-Barr virus biology. Semin Cancer Biol 19: 377-388.
46. Rui L, Schmitz R, Ceribelli M, Staudt LM. 2011. Malignant pirates of the immune system. Nat Immunol 12: 933-940.
47. Sander S, Calado DP, Srinivasan L, Kochert K, Zhang B, Rosolowski M, Rodig SJ, Holzmann K, Stilgenbauer S, Siebert R, et al. 2012. Synergy between PI3K signaling and MYC in Burkitt lymphomagenesis. Cancer Cell 22: 167-179.
48. Schmitz R, Young RM, Ceribelli M, Jhavar S, Xiao W, Zhang M, Wright G, Shaffer AL, Hodson DJ, Buras E, et al. 2012. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature 490: 116-120.
49. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al. 2005. Gene set enrichment analysis: A knowledge-based approach for interpreting genomewide expression profiles. Proc Natl Acad Sci 102: 15545-15550.
50. Taub R, Kirsch I, Morton C, Lenoir G, Swan D, Tronick S, Aaronson S, Leder P. 1982. Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells. Proc Natl Acad Sci 79: 7837-7841.
51. Thorley-Lawson DA. 2001. Epstein-Barr virus: Exploiting the immune system. Nat Rev Immunol 1: 75-82.
52. Vereide DT, Sugden B. 2011. Lymphomas differ in their dependence on Epstein-Barr virus. Blood 117: 1977-1985.
53. Victora GD, Nussenzweig MC. 2012. Germinal centers. Annu Rev Immunol 30: 429-457.
54. Victora GD, Dominguez-Sola D, Holmes AB, Deroubaix S, Dalla-Favera R, Nussenzweig MC. 2012. Identification of human germinal center light and dark zone cells and their relationship to human B-cell lymphomas. Blood 120: 2240-2248.
55. Wilson JB, Bell JL, Levine AJ. 1996. Expression of Epstein-Barr virus nuclear antigen-1 induces B cell neoplasia in transgenic mice. EMBO J 15: 3117-3126.
56. Wright GW, Simon RM. 2003. A random variance model for detection of differential gene expression in small microarray experiments. Bioinformatics 19: 2448-2455.
57. Xiao C, Srinivasan L, Calado DP, Patterson HC, Zhang B, Wang J, Henderson JM, Kutok JL, Rajewsky K. 2008. Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat Immunol 9: 405-414.
58. Young RM, Staudt LM. 2013. Targeting pathological B cell receptor signalling in lymphoid malignancies. Nat Rev Drug Discov 12: 229-243.
59. Yustein JT, Dang CV. 2007. Biology and treatment of Burkitt's lymphoma. Curr Opin Hematol 14: 375-381.
60. Zech L, Haglund U, Nilsson K, Klein G. 1976. Characteristic chromosomal abnormalities in biopsies and lymphoidcell lines from patients with Burkitt and non-Burkitt lymphomas. Int J Cancer 17: 47-56.
61. Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA, Magoon D, Qi J, Blatt K, Wunderlich M, et al. 2011. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 478: 524-528.